Use of the Ketamine Metabolite (R,6R)-hydroxynorketamine in Depression

Description:
This technology includes the identification and use of a ketamine metabolite, (2R,6R)-2-amino-2-(2-chlorophenyl)-6-hydroxycyclohexanone (HNK), for the treatment of depression. Ketamine is an NMDA receptor antagonist that exerts a rapid and sustained antidepressant and anti-suicidal effect. However, even low doses of ketamine has addictive and psychomimetic effects. The downstream metabolite, (2R,6R)-HNK, does not inhibit the NMDA receptor but recapitulates the antidepressant and anti-suicidal effect of ketamine. Further clinical work could establish a ketamine metabolite, such as (2R,6R)-HNK, for the treatment of depression.
Patent Information:
For Information, Contact:
Suryanarayana Vepa
Technology Licensing Specialist
NIH Technology Transfer
301-827-7181
sury.vepa@nih.gov
Inventors:
Todd Gould
Irving Wainer
Carlos Zarate
Ruin Moaddel
Patrick Morris
Panos Zanos
Craig Thomas
Keywords:
2R
6R-hydroxynorketamine
depression
Ketamine
METABOLITE
VEXXXX
VNXXXX
WIXXXX
WKXXXX
© 2024. All Rights Reserved. Powered by Inteum